<?xml version="1.0" encoding="UTF-8"?>
<p>The assessment of safety of IP is an important component of any clinical trial. In patients suffering from SARS, severity of disease, use of variety of medical procedures, underlying comorbidity, and use of concomitant treatments make detection of potential adverse effects of IP complex and difficult. In Ebola studies, the investigators monitored the patients for adverse events (AEs) not corresponding to symptoms of Ebola virus disease and focused on AEs of favipiravir described in the previous trials of influenza infection.[
 <xref rid="ref7" ref-type="bibr">7</xref>] In the LOTUS China study, gastrointestinal AEs were more common in lopinavir–ritonavir group than in the standard-care group.[
 <xref rid="ref1" ref-type="bibr">1</xref>] The incidence of serious AEs was lopinavir–ritonavir group: 20% and standard-care group: 32.3%. There were four gastrointestinal SAEs in the drug group. All deaths were assessed by the researchers to be unrelated to the drugs.
</p>
